Tuberculosis diagnostics technology & market landscape – semi-annual update
Malaria diagnostics market landscape – semi-annual update
HIV/AIDS diagnostics technology landscape – semi-annual update
Hepatitis C medicines and diagnostics in the context of HIV/HCV co-infection: a scoping report
Tuberculosis medicines technology and market landscape – 1st edition
HIV preventives technology and market landscape – 1st edition
Tuberculosis diagnostics technology and market landscape – 2nd edition
HIV/AIDS diagnostics technology landscape – 3rd edition
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Biomarkers for acute febrile illness at the point-of-care in low-resource settings. Meeting report
Accelerating access to innovative point-of-care HIV diagnostics: Lessons learned from UNICEF
Innovative delivery systems for paediatric medicines technology landscape
Disease Narrative for hepatitis C
Disease narrative for tuberculosis
Disease Narrative for malaria
Disease Narrative for HIV
Hepatitis C diagnostics technology landscape – May 2019
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Key Performance Indicators 2009
Unitaid transparency policy
Policy on ethics and conflict of interest for Unitaid
